| 參考文獻 |
References
1 C. Han, and B. Wang, “Factors that impact the developability of drug candidates: an overview,” Chapter 1 in Drug delivery: principles and applications, edited by B. Wang, T. Siahaan, and R. Soltero, (John Wiley & Sons, 2005) pp. 1-5.
2 K. Sweeny, “Technology trends in drug discovery and development: implications for the development of the pharmaceutical industry in Australia”, draft working paper No. 3, pharmaceutical industry project, CSES, Victoria University, Melbourne.
3 M. S. Lipsky, and L. K. sharp, “From idea to market: the drug approval process,” JABFP, 14(5), 326-367 (2001).
4 S. Kraljevic, P. J. Stambrook, and K. Pavelic, “Acceleration drug discovery,” EMBP reports, 5(9), 837-842 (2004).
5 G. W. Galdwell, “Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinectic properties utilizing combined phtsicochemical, in vitro and in vivo screens,” Cut. Opin. Drug Disc. Dev., 3(1), 30-41 (2000).
6 L. Yu, S. M. Reutzel, and G. A. Stephen, “Physical characterization of polymorphic drugs: an integrated characterization strategy.” PSTT, 1(3), 118-127 (1998).
7 Y. Yoswhihashi, E. Yonemochi and K. Terada, “Estimation of initial dissolution rate of drug substance by thermal analysis: application for carbamazepine hydrate.” Pharm. Devel. Tech.,
7(1), 89-95 (2002).
8 D. J. W. Grant, “Theory and origin of polymorphism,” Chapter 1 in Polymorphism in pharmaceutical solids, Edited by H.G. Brittain, (Marcel Dekker, INC. New York, 1999) pp. 1-33.
9 L. X. Yu, M. S. Furness, A. Raw, K. P. W. Outlaw, N. E. Nashed, E. Ramos, S. P. F. Miller, R. C. Adams, F. Fang, R. M. Patel, F. O. Holcombe, Jr., Y. Y. Chiu, and A. S. Hussain, “Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications,” Pharm. Res., 20(4), 531-536 (2003).
10 T. L. Threlfall, “ Analysis of organic polymorphs a review,” Analyst., 120(10), 2435-2459 (1995).
11 M. Fujiwara, Z. K. Nagy, J. W. Chew, and R. D. Braatz, “First-priciples and direct design approaches for the control of pharmaceutical crystallization,” J. Process. Control., 15(5), 493-504 (2005).
12 N. A. Lewis, “A tracking tool for lean solid-dose manufacturing,” Pharm. Tech., 30(10), 94-108 (2006).
13 A. Kadir, B. H. Ali, G. A. Hadrami, A. K. Bashir, M. F. Landoni, and P. Lees, “Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (camelus dromedarius),” J. Vet. Pharmacol. Therap., 20(1), 54-60 (1997).
12
14 M. D. Tuladhar, J. E. Carles, and M. P. Summers, “Thermal behavior and dissolution properties of phenylbutazone polymorphs,” J. Pharm. Pharmacol., 35(4): 208-214 (1983).
15 H. G. Ibahim , F. Pisano, and A. Bruno, “Polymorphism of penylbutazone: properties and compressional behavior of crystals,” J. Pharm. Sci., 66(5), 669-673 (1977).
16 N. Kaneniwa, J. Ichikawa, and T. Matsumoto, “ Preparation of phenylbutazone polymorphs and their transformation in solution,” Chem. Pharm. Bull., 36(3) 1063-1073 (1988).
17 H. H. Paradies, “Structure of phenylbutazone and mofebutazone in the crystalline state and in solution,” J. Pharm. Sci., 76(12), 919-929 (1987).
18 S. Datta, and D. J. W. Grant, “Computing the relative nucleation rate of phenylbutazone and sulfamerazine in various solvents,” Cryst. Growth Des., 5(4), 1351-1357 (2005).
19 T. Hosokawa, S. Datta, A. R. Sheth, and D. J. W. Grant, “Relationship between crystal structures and thermodynamic properties of phenylbutazone solvates,” Cryst. Eng. Comm, 6(44), 243-249 (2004).
20 N. G. Anderson, “Solvent selection,” Chapter 4 in Practical Process Research & Development (Academic Press, New York, 2000) pp. 81-111.
21 T. Lee, C. S. Kuo, and Y. H. Chen, “Solubility, polymorphism, crystallinity, and crystal habit of acetaminophen and ibuprofen by initial solvent screening,” Pharm. Tech., 30(10), 72-92 (2006).
13
22 T. Lee, and F. B. Hsu, “A cross-performance relationship between carr’s index and dissolution rate constant: the study of acetaminophen batches,” Drug Dev. Ind. Pharm., 33(11), 1273-1284 (2007).
23 T. Lee, H. J. Hou, H. Y. Hsieh, Y. C. Su, Y. W. Wang, and F. B. Hsu, “The prediction of the dissolution Rate constant by mixing rules: the study of acetaminophen batches,” Drug Dev. Ind. Pharm., 34(5), 522-535 (2008).
24 Á. Beretzky, P. Kása Jr., K. Pintye-Hódi, J. Bajdik, P. Szabó-Révész, and I. Erõs, “Pelletization of needle-shaped phenylbutazone crystals,” J. Therm. Anal. Calorim., 69(2), 525-539 (2002).
25 A. Nokhodchi, M. Maghsoodi, D. Hassan-Zadeh, and M. Barzegar-Jalali, “Preparation of agglomerated crystals for improving flowability and compactibility of poorly flowable and compactible drugs and excipients,” Powder Tech., 175(2), 73-81 (2007).
26 T. Threlfal, “Crystallizatopn of polymorphs: thermodynamic insight into the role of solvent,” Org. Process Res. Dev., 4(5), 384-390 (2000).
1 D. J. W. G.rant, “Theory and origin of polymorphism,” Chapter 1 in Polymorphism in pharmaceutical solids, edited by H. G. Brittain, (Marcel Dekker, Inc., New York, 1999) pp. 1-21.
2 T. L. Threlfall, “Analysis of organic polymorphs: a review,” Analyst, 120(10), 2435-2460 (1995).
3 V. Koradia, G. Chawla, and A. K. Bansal, “Qualitive and quantitative analysis of clopidogrel bisulphate polymorphs,” Acta Pharm. 54(3), 193-204 (2004)
4 T. Hosokawa, S.Datta, A. R. Sheth and D. J. W. Grant, “Relationships between crystal structures and thermodynamic properties of phenylbutazone solvates,” Cryst. Eng. Comm. 6(44), 243-249 (2004).
5 G. Chawala, and A. K. Bansal, “Challenges in polymorphism of pharmaceuticals,” CRIPS 5(1), 9-12 (2004).
6 S. Mirza, I. Miroshnyk, J. Heinamaki, L. Christiansen, M. Karjalainen, and J. Yliruusi, “Influence of solvents on the variety of crystalline forms of erythromycin,” AAPS Pharm. Sci. 5(3), 1-9 (2003).
7 P. Di Martino, A-M. Guyot-Hermann, P. Conflant, M. Drache, and J-C. Guyot, “A new pure paracetmol for direct compression: the orthorhombic form,” Int. J. Pharm., 128(1-2), 1-8 (1996).
8 L. Yu, S. M. Reutzel, and G.. A. Stephenson, “Physical characterization of polymorphic drugs: an integrated characterization strategy,” PSTT, 1(3), 118-127 (1998).
9 N. V. Phadnis , R. K. Cavatur, and R. Suryanarayanan, “Identification of drugs in pharmaceutical dosage forms by X-ray powder diffractometry,” J Pharm Biomed Anal., 15(7), 929-943 (1997).
10 G. Nichols, and C. S. Frampton, “Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution,” J. Pharm. Sci., 87(6), 684-693 (1998).
11 E. V. Boldyerva, V. A. Drebushchak, I. E. Paukov, Y. A. Kovalevskaya, and T. N. Drebushchak, “DSC and adiabatic calorimetry study of the polymorphs of paracetamol,” J. of Them. Anal. Calor., 77(2), 607-623 (2004).
12 D. Giron, “Thermal analysis and calorimetric methods in the characterization of polymorphs and solvate,” Thermochim. Acta, 248(1), 1-59 (1995).
13 B. R. Spong, C. P. Price, A. Jayasankar, A. J. Matzger, and N. R. Horndo, “General principles of pharmaceutical solid polymorphism a supramolecular perspective,” Adv. Drug Del. Rev., 56(3), 241-274 (2004).
14 G. W. Smith, “Precipitation kinetics in an air-cooled aluminum alloy: a composition of scaning and isothermal calorimetry measurement methods,” Thermochim. Acta, 313(1), 27-36 (1998).
33
15 T. Hatakeyama, and Z. Liu, “Conformation of TA apparatus,” Chapter 2 in Handbook of thermal analysis, 1st edition, (John Wiley & Sons, Baffins Lane, England, 1998) pp. 17-19.
16 K. L. A. Chan, and S. G. Kazarian, “Fourier transform infrared imaging for high-throughput analysis of pharmaceutical formulation,” J. Comb. Chem.,
7(2), 185-189 (2005).
17 N. S. Murthy, and F. Reidinger, “X-ray analysis,” Chapter 7 in Matericals characterization and chemical analysis, (J. P. Sibilia, Wiley-Vch , New York, USA, 1996) pp. 143-149.
18 M. Davidovich, J. Dimarco, J. Z. Gougoutas, R. P. Scaringe, I. Vitez, S. Yin, “Detection of polymorphic artifacts in powder x-ray diffraction determination,” Am. Pharm. Rev., 138 (1), 1-2 (1996).
19 J. E. Macur, J. Marti, and S. C. Lui, “Microscopy,” Chapter 8 in Matericals characterization and chemical analysis, , 2nd edition, (J. P. Sibilia, Wiley-Vch, New York, USA, 1996) pp. 167-177.
20 K. Gotoh, H. Masuda, and K. Higashitani, “Powder-handling operation,” Chapter 5 in Powder technology handbook, 2nd edition, (Marcel Dekker, Inc, New York, 1997) pp. 413-730
References
1 B. Shekunov, and P. York,“Crystallization processes in pharmaceutical technology and drug delivery design,” J. Crystal Growth, 211(1), 122–136 (2000).
2 D. J. W. Grant, “Theory and origin of polymorphism,” Chapter 1 in Polymorphism in pharmaceutical solids, edited by H. G. Brittain, (Marcel Dekker, INC., New York, 1999) pp. 1-21.
3 C. U. Yurteri, M. K. Mazumder, N. Grable, G. Ahuja, S. Trigwell, A. S. Biris, R. Sharma, and R. A. Sims, “Electrostatic effects on dispersion, transport, and deposition of fine pharmaceutical powders: development of an experiment method for quantitative analysis,” Particulate Sci. Tech. 20(1), 59-79 (2002).
4 M. E. Möbius, B. E. Lauderdale, S. R. Nagel, and H. M. Jaeger, “Brazail-nut effect: size separation of granular particles,” Nature 414, 270 (2001).
5 G. K. Bolhuis, and Z. T. Chowhan, “Material for direct compaction,” in Pharmaceutical Powder Compaction Technology, G. ALderborn and C. Nystrom, Eds. (Marcel Dekker, New York, NY, 1996), Ch. 14, pp. 419-500.
6 M. D. Tousey, “The granulation process 101: basic technologies for tablet marking,” Pharm. Technol. 26 (Tableting and Granulation), 8-13 (2002).
7 G. W. Gereg, and M. L. Coppola, “Roller compaction feasibility studies for new drug candidates-laboratory to production scale,” Pharm.Technol., 26 (Tableting and Granulation),
14-23 (2002).
8 P. York “Solid-state properties of powders in the formulation and processing of solid dosage forms.” Int. J. Pharm., 14(1), 1-28 (1983).
9 P. V. Marshal, and P. York, “Crystallization solvent induced solid-state and particulate modifications of nitrofurantoin,” Int. J. Pharm., 55(2-3), 257-263 (1989).
10 A. Florence, and D. Attwood, “Physicochemical principles of pharmacy,” 3rd ed. (Macmillan Press, London, 1998) pp. 5-35.
11 D. J. W. Grant, “Approaches to polymorphism screening,” chapter 11 in Polymorphism in pharmaceutical solids, edited by H. G. Brittain, ( Marcel Dekker, INC., New York, 1999) p. 289.
12 W. Beckman, W. Otto, and W. Budde, “Crystallisation of the stable polymorph of hydroxytriendione: seeding process and effects of purity,” Org. Proc. Res. Dev., 5 ( 4 ), 387-392 (2001).
13 R. Hilfiker, J. Berghausen, F. Blatter, A. Burkhard, S. M. D. Paul, B. Freiermuth, A. Geoffroy, U. Hofmeier, C. Marcolli, B. Siebenhaar, M. Szelagiewicz, A. Vit, and M. V. Raumer, “Polymorphism-integrated approach from high-throughput screening to crystallization optimization,” J. Therm. Anal. Calorim., 73(2), 429-440 (2003).
87
14 A. Kadir, B. H. Ali, G. A. Hadrami, A. K. Bashir, M. F. Landoni, and P. Lees, “Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (camelus dromedarius),” J. Vet. Pharmacol. Therap., 20(1), 54-60 (1997).
15 H. H. Paradies, “Structure of phenylbutazone and mofebutazone in the crystalline state and in solution,” J. Pharm. Sci., 76(12), 919-929 (1987).
16 S. N. Bhattachar, L. A. Deschenesa, and J. A. Wesleya, “Solubility: it is not just for physical chemists,” Drug Discovery Today, 11(21-22), 1012-1018 (2006)
17 J. W. Mullin, “solution and solubility,” Chapter 3 in Crystallization, 3rd edition, (Butterworth-Heinemann, London, 1992), p. 82
18 C. J. Price, “Take some solid steps to improve crystallization,” Chem. Eng. Prog., 93(9), 34-43 (1997).
19 K. Srinivasan, S. Anbukumar, and P. Ramasamy, “Mutual solubility and metastable zone width of NH4H2PO4-KHAPO4 mixed solutions and growth of mixed crystals,” J. Cryst. Growth, 151(1), 226-229 (1995).
20 J. Berstein, R. J. Davey, and J-O. Henck, “Concomitant polymorphs,” Angew.
Chem. Int. Ed. 38(23), 3440-3461 (1999).
21 D. Giron, “Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates,” Thermochim. Acta, 248(1), 1-59 (1995).
88
22 R. J. Behme, and D. Brooke, “Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis,” J. Pharm. Sci., 80(10), 986-990 (1991).
23 T. Threlfall, “Crystallization of polymorph: thermodynamic in sight into the role of solvent,” Org. Process Res. Dev., 4(5), 384-390 (2000)
24 M. Charoenchaitrakool, F. Dehghani, and N. R. Foster, “Micronization by rapid expansion of supercritical solutions to enhance the dissolution rates of poorly water-soluble pharmaceuticals.” Ind. Eng. Chem. Res., 39 (12), 4794 -4802 (2000).
25 A. Florence, and D. Attwood, “Physicochemical principles of pharmacy,” 3rd edition (Macmillan Press Ltd., London, 1998) pp. 5-35.
26 J. W. Mullin, “Solution and solubility,” Chapter 3 in Crystallization, 3rd edition, (Butterworth-Heinemann, London, 1992) p.248.
27 M. Lahav, and L. Leiserowitz, “The effect of solvent on crystal growth and morphology”, Chem. Eng. Sci., 56(7), 2245-2253 (2001).
28 C. Stoica, P. Verwer. H. Meekes, P. J. C. M. van Hoof, F.M. Kaspersen, and E. Vlieg, “Understanding the effect of a solvent on the crystal habit,” Cryst. Growth Des., 4(4), 765-768 (2004).
89
29 N. Rasenack, and B. W. Muller, “Crystal habit and tableting behavior,” Int. J. Pharm., 244(1-2), 45-57 (2002).
30 A. K. Tiwary, “Modification of crystal habit and its role in dosage form performance,” Drug Dev. Ind. Pharm., 27(7), 699-709 (2001).
31 A. F. M. Barton, “Handbook of solubility parameters and other cohesion parameter,” 2nd edition, (CRC Press, USA, 1991) pp.69-149.
32 T. Lee, Y. H. Chen, and C. W. Zhang. (2007). Solubility, polymorphism, crystallinity, crystal habit, and drying scheme of (R, S)-(±)-sodium ibuprofen dihydrate. Pharm. Tech., 31(6), 72-87.
33 M. D. Tuladhar, J. E. Carles, and M. P. Summers, “Thermal behavior and dissolution properties of phenylbutazone polymorphs,” J. Pharm. Pharmacol., 35: 208-214 (1983).
34 N. G. Anderson, Practical Process Research & Development (Academic Press, New York, NY, 2000), pp. 81-111.
35 T. Lee, C. S. Kuo, and Y. H. Chen., “Solubility, polymorphism, crystallinity, and crystal habit of acetaminophen and ibuprofen by initial solvent screening,” Pharm. Tech., 30(10), 72-92 (2006).
36 H. G. Ibahim, F. Pisano, and A. Bruno, “Polymorphism of phenylbutazone: properties and
90
compressional behavior of crystals,” J. Pharm. Sci., 66(5), 669-673 (1977).
37 N. Kaneniwa, J. Ichikawa, and T. Matsumoto, “Preparation of phenylbutazone polymorphs and their transformation in solution,” Chem. Pharm. Bull., 36(3) 1063-1073 (1988).
38 T. Hosokawa, S. Datta, A. R. Sheth, and D. J. W. Grant, “Relationship between crystal structures and thermodynamic properties of phenylbutazone solvates,” Cryst. Eng. Comm, 6(44), 243-249 (2004).
39 T. Hosokawa, S. Datta, A. R. Sheth, N. R. Brooks, V. G. Young, and D. J. W. Grant, “Isostructurality among five solvates of phenylbutazone,” Cryst. Growth Des., 4(6), 1195-1201 (2004).
References
1 M. Asada, H. Takahashi, H. Okamoto, H. Tanino, and K. Danjo, “Theophylline particle design using chitison by spray drying,” Int. J. Pharm. 270(1-2), 167-174 (2004).
2 J. Straatsma, G.. V. Houwelingen, and A. E. Steenbergen, “Spray drying of food products: 1. Simulation model,” J. Food Eng. 42(2), 67-72 (1999).
3 J. Katta, and A. C. Rasmuson, “Spherical crystallization of benzoic acid,” Int. J. Pharmaceut., 348(1-2), 61-69 (2008).
4 S. Bhadra, and M. Kumar, Sunil Jain, S. Agrawal, and G. P. Agrawal, “Spherical crystallization of mefenamic acid,” Pharm. Tech., 28(1), 66-76 (2004).
5 A. Nokhodchi, M. Maghsoodi, D. Hassan-Zadeh, and M. Barzegar-Jalali, “Preparation of agglomerated crystals for improving flowability and compactibility of poorly flowable and compactible drugs and excipients,” Powder Tech., 175(2), 73-81 (2007).
6 K. I. Popov, S. Krsti, M. Obradovi, M. G. Pavlovi, L. Pavlovi, and V. Ivanovi, “The effect of the particle shape and structure on the flowability of electrolytic copper powder.I. Modeling of a representative powder particle,” J. Serb. Chem. Soc., 68(10), 771–777 (2003)
7 Y. Kawashima, M. Imai, H. Takeuchi, H. Yamamoto, K. Kamiya, and T. Hino, “Improved flowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct
for direct tableting designed by spherical crystallization process,” Powder Tech., 130 (1), 283-289 (2003).
8 H. Goczo, P. S. Revesz, B. Farkas, M. Hasznos-Nezdei, S. F. Serwanis, K. Pinyye-Hodi, P. Kasa, Jr., I. S. Eros, I. Antal, and S. Marton, “Development of spherical crystals of acetylsalicylic acid for direct tablet-making,” Chem. Pharm. Bull., 48(12), 1877-1881 (2000).
9 A. S. Utada, L. Y. Chu, A. Fernandez-Nieves, D. R. Link, C. Holtze, and D. A. Weitz, “Dripping, jetting, drops, and wetting: the magic of microfluics,” MRS BULLETIN, 32, 702-708 (2007).
10 U. Teipel, T. Heintz, and H. H. Krause, “Crystallization of spherical ammonium dinitramide (AND) particles,” Propellant, Explosives, Pyrotechnics, 25(8), 81-85 (2000).
11 A. R. Paradkar, K. R. Mahadik, and A. P. Pawar, “Spherical crystallization a novel particle design technique,” Indian Drug, 31(6), 283-299 (1998).
12 Y. Kawashima, H.Takeuchi, T. Niwa, and T. Hino, “The development of a novel emulsion-solvent-diffusion preparation method of agglomerated crystals for direct tableting and evaluation of their compressibilities,” J. Soc. Powder Tchnol. Japan, 26, 659-665 (1989).
13 D. Amaro-González, and B. Biscans, “Spherical agglomeration during crystallization of an active pharmaceutical ingredient,” Powder Tech., 128(2), 188-194 (2002).
129
14 A. Sano, T. Kuriki, Y. Kawashima, H. Takeuchi, and T. Niwa, “Particle design of tolbutamide by spherical crystallization technique. II. Factors causing polymoepism of tolbutamide spherical agglomerates,” Chem. Pharm. Bull., 37(8), 2183-2187 (1989).
15 Y. Kawashima, M. Okumura, and H. Takenake, “Spherical crystallization: direct spherical agglomeration of salicylic acid crystals during crystallization,” Science, 216(4550), 1127-1128 (1982).
16 K. Morishima, Y. Kawashima, and H. Takeuchi, “Micromeritic characteristics and agglomeration mechanisms in the spherical crystallization of bucillamine by the spherical agglomeration and the emulsion solvent diffusion methods,” Powder Technol., 76(1), 57-64 (1993).
17 K. Kachrimanis, I. Nikolakakis, and S. Malamataris, “Spherical crystal agglomeration of ibuprofen by the solvent-change technique in presence of methacrylic polymers,” J. Pharm. Sci., 89(2), 250-259 (2000).
18 A. Ribardière, P. Tchoreloff, G. Couarraze, and F. Puisieux, “Modification of ketoprofen bead structure produced by the spherical crystallization technique with a two-solvent system,” Int. J. Pharm., 144(2), 195-207 (1996).
19 Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, Y. Itoh, and S. Furuyama, “Characterization of polymorph of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques,” J. Pharm. Sci., 80(5), 472-478 (1991).
130
20 Y. Kawashima, S. Aoki, H. Takenaka, and Y. Miyake, “Preparation of spherically agglomerated crystals of aminophylline,” J. Pharm. Sci., 73(10), 1407-1410 (1984).
21 Y. Kawashima, S. Y. Lin, M. Naito, and H. Takenaka, “Direct agglomeration of sodium theophylline crystals produced by salting out in liquid,” Chen. Pharm. Bull., 30(5), 1837-1843 (1981).
22 Y. Kawashima, M. Okumura, and H. Takenaka, “The effect of temperature on the spherical crystallization of salicylic acid,” Powder Technol., 39(1), 41-47 (1984).
23 A. Sano, T. Kuriki, Y. Kawashima, H. Takeuchi, T. Hino, and T. Niwa, “Particle design of tolbutamide by spherical crystallization technique. III. Micrometric properties and dissolution rate of tobutamide spherical agglomerates prepared by the quasi-emulsion solvent diffusion method and the solvent change method,” Chem. Pharm. Bull., 38(3), 733-739 (1990).
24 H. L. Chow, and W. M. Leng, “A study of the mechanisms of wet spherical agglomeration of pharmaceutical powders,” Drug Dev. Ind. Pharm., 22(4). 357-371 (1996).
25 M. Jbilou, A. Ettabia, A. M. Guyot-Hermann, and J. C. Guyot, “Ibuprofen agglomerates preparation by phase separation,” Drug Dev. Ind. Pharm., 25(3), 297-305 (1999).
26 P. D. Martino, C. Barthelemy, F. Piva, E, Joiris, G. F. Palmieri, and S. Martelli, “ Improved dissolution behavior of fenbufen by spherical crystallization,” Drug Dev. Ind. Pharm., 25(10), 1073-1081 (1999).
131
27 M. Nocent, L. Bertocchi, F. Espitalier, M. Baron, and G. Couarraze, “Definition of a solvent system for spherical crystallization of salbutamol sulfate by quasi-emulsion solvent diffusion (QESD) Method,” J. Pharm. Sci., 90(10), 1620-1627.
28 A. R. Paradkar, A. P. Pawar, J. K. Chordiya, V. B. Patil, and A. R. Ketkar, “Spherical crystallization of celecoxib,” Drug Dev. Ind. Pharm. 28(10), 1213-1220 (2002).
29 A. P. Pawar, A. R. Paradkar, S. S. Kadam, and K. R. M.ahadik, “Crystallo-co-agglomeration: a novel to obtain ibuprofen-paracetamol agglomerates,” AAPS Pharm. Sci. Tech., 5(3), 1-7 (2004).
30 Á. Beretzky, P. Kása Jr.,K. Pintye-Hódi, J. Bajdik, P. Szabó-Révész, and I. Erõs, “Pelletization of needle-shaped phenylbutazone crystals,” J. Therm. Anal. Calorim., 69(2), 525-539 (2002).
31 H. H. Paradies, “Structure of phenylbutazone and mofebutazone in the crystalline state and in solution,” J. Pharm. Sci., 76(12), 919-929 (1987).
32 M. D. Tuladhar, J. E. Carless, and M. P. Summer, “Thermal behavior and dissolution properties of phenylbutazone polymorphs,” J. Pharm. Pharmacol., 35(4), 208-214 (1983).
33 H. G. Ibahim, F. Pisano, and A. Bruno, “Polymorphism of phenylbutazone: properties and compressional behavior of crystals,” J. Pharm. Sci., 66(5), 669-673 (1977).
34 T. Lee, and S. T. Hung, “Cocktail-solvent screening to enhance solubility, increase crystal
132
yield, and induce polymorph,” Pharm. Tech., 32(1), 76-95 (2008).
35 W. Beckmann, “Seeding the desired polymorph: background, possibilities, limitations, and case studies,” Org. Proc. Res. Dev., 4(5), 372-383 (2000).
36 N. G. Anderson, Practical Process Research & Development (Academic Press, New York, NY, 2000), pp. 81-111.
37 D. J. C. Constable, C. Jimenez-Gonzalez, and R. K. Henderson, “Perspective on solvent use in the pharmaceutical industry,” Org. Process Res. Dev., 11(1), 133-137 (2007).
38 K. J. Kim, and A. Mersmann, “Estimation of meta-stable zone width in different nucleation processes,” Chem. Eng. Sci., 56 (7), 2315-2324 (2001).
39 A. Y. Huang, and J. C. Berg, “Gelation of liquid bridges in spherical agglomeration,” Colloids Surf., A, 215(1-3), 241-252 (2003).
40 N. Kaneniwa, J. Ichikawa, and T. Matsumoto, “Preparation of phenylbutazone polymorphs and their transformation in solution,” Chem. Pharm. Bull., 36(3), 1063-1073 (1988).
41 Y. Matsuda, S. Kawaguchi, H. Kobayashi, and J. Nishijo, “Physicochemical characterization of spray-dried phenylbutazone polymorphs,” J. Pharm. Sci., 73(2), 173-179 (1984).
Reference
1 Y. Matsuda, S. Kawaguchi, H. Kobayashi, and J. Nishijo, “Physicochemical characterization of spray-dried phenylbutazone polymorphs,” J. Pharm. Sci., 73(2), 173-179 (1984). |
[Endnote RIS 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
[檢視]
plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
Google bookmarks
del.icio.us
hemidemi
facebook
twitter
google
reddit